Maynard Um
-
-
-
-
-
-
-
AstraZeneca reviews potential Bristol Myers deal, Barclays comments
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) call put ratio 6.8 calls to 1 put with a focus on spreader of 8244 contracts of June and July 57.50 calls
-
-
-
-
-
-
-
Bristol Myers Squibb to present 60+ oncology studies at ASCO 2026
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at BMO Capital
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Reiterated at Neutral by Cantor Fitzgerald on Eliquis Outlook
-
-
-
-
-
-
-
Bristol Myers Squibb wins FDA and EU approvals for Opdivo in Hodgkin lymphoma
-
433,624 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

